FDA Approves New Oral Medication for High Cholesterol

The FDA has granted approval for Lipfendra, a novel oral medication from Merck, designed to significantly lower cholesterol levels in high-risk patients whose condition persists despite statin therapy. This marks the introduction of the first non-injectable PCSK9 inhibitor, providing a new treatment option. Clinical trials demonstrated that Lipfendra could reduce LDL cholesterol by over 55% in some individuals.